Neuromyelitis optica spectrum disorder in Germany: A claims data analysis of incidence, prevalence, treatment patterns, and diagnostic overlap with multiple sclerosis
Authors:
Open Access
- 1 April 2026
- journal article
- research article
- Published by SAGE Publications in Multiple Sclerosis Journal – Experimental, Translational and Clinical
- Vol. 12 (2)
Abstract
Background: Neuromyelitis optica spectrum disorders (NMOSD) are rare autoimmune diseases of the central nervous system. Global prevalence estimates vary widely, and data for Germany are limited. Objectives: To estimate NMOSD prevalence, incidence, diagnostic settings, comorbid coding with multiple sclerosis (MS), and treatment patterns in Germany. Methods: We analyzed German BARMER health insurance claims data (approximately 9 million persons; 2015–2022). NMOSD cases were identified by ICD-10-GM code G36.0. Frequencies, diagnostic settings, comorbid MS coding (G35.-), and treatment patterns (Anatomical Therapeutic Chemical codes) were assessed. Results: We identified 527 incident NMOSD cases (0.82 per 100,000 insured persons per year); 69% were female, and 42% aged 40–59 years. Most diagnoses occurred in outpatient care (63%), primarily by neurologists (48%) or general practitioners (28%). Prevalence increased from 2.9 to 4.7 per 100,000 between 2015 and 2022, while NMOSD-specific medication use rose from 16% to 31%. NMOSD and MS codes co-occurred in 64% of cases; 49% had concurrent diagnoses within 9 months, and 42% were first diagnosed with MS. Conclusion: NMOSD prevalence and incidence in Germany are increasing, with frequent diagnostic overlap with MS. Findings highlight the need for improved diagnostic differentiation and early specialist involvement.Keywords
This publication has 33 references indexed in Scilit:
- The impact of autoimmune comorbidities on the onset attack recovery in adults with AQP4-NMOSD and MOGADJournal of Neurology, 2025
- Magnetic resonance imaging-based biomarkers of multiple sclerosis and neuromyelitis optica spectrum disorder: a systematic review and meta-analysisJournal of Neurology, 2024
- Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term managementJournal of Neurology, 2023
- Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosisJournal of Neurology, 2023
- Ravulizumab in Aquaporin‐4–Positive Neuromyelitis Optica Spectrum DisorderAnnals of Neurology, 2023
- Worldwide prevalence of neuromyelitis optica spectrum disorder (NMOSD) and neuromyelitis optica (NMO): a systematic review and meta-analysisNeurological Sciences, 2023
- Factors associated with the misdiagnosis of neuromyelitis optica spectrum disorderMultiple Sclerosis and Related Disorders, 2023
- Evaluating the Economic Burden of Relapses in Neuromyelitis Optica Spectrum Disorder: A Real-World Analysis Using German Claims DataNeurology and Therapy, 2021
- Neuromyelitis Spectrum DisordersMayo Clinic Proceedings, 2017
- Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS)Journal of Neurology, 2013